Trial NCT03192345

View at ClinicalTrials.gov 
Org. Study IDs: TCD14678
Secondary IDs: 2018-001113-32

Last trial update was posted on 2022-05-12

MeSH Interventions

Cemiplimab

MeSH Conditions

Neoplasms

Other Conditions

Malignant Solid Tumor

Stopping Reasons

Occurrence of objective responses in multiple indications in the Phase 1b was not enough to warrant further exploration in view of competitive landscape and some toxicity (mostly bleeding events).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID